Hostname: page-component-78c5997874-j824f Total loading time: 0 Render date: 2024-11-05T06:36:43.075Z Has data issue: false hasContentIssue false
  • English
  • Français

A case of social phobia and avoidant personality disorder with erectile dysfunction successfully treated with venlafaxine and add-on reboxetine

Published online by Cambridge University Press:  16 April 2020

Isabella Pacchiarotti ,
Giovanni Manfredi ,
Giorgio D. Kotzalidis ,
Amedeo Ruberto ,
Roberto Tatarelli  and
Paolo Girardi
Isabella Pacchiarotti*
Affiliation:
Department of Psychiatry, University of Rome, “La Sapienza”-Sant’Andrea Hospital, 1035-1039 Via di Grottarossa, 00189Rome, Italy
Giovanni Manfredi
Affiliation:
Department of Psychiatry, University of Rome, “La Sapienza”-Sant’Andrea Hospital, 1035-1039 Via di Grottarossa, 00189Rome, Italy
Giorgio D. Kotzalidis
Affiliation:
Department of Psychiatry, University of Rome, “La Sapienza”-Sant’Andrea Hospital, 1035-1039 Via di Grottarossa, 00189Rome, Italy
Amedeo Ruberto
Affiliation:
Department of Psychiatry, University of Rome, “La Sapienza”-Sant’Andrea Hospital, 1035-1039 Via di Grottarossa, 00189Rome, Italy
Roberto Tatarelli
Affiliation:
Department of Psychiatry, University of Rome, “La Sapienza”-Sant’Andrea Hospital, 1035-1039 Via di Grottarossa, 00189Rome, Italy
Paolo Girardi
Affiliation:
Department of Psychiatry, University of Rome, “La Sapienza”-Sant’Andrea Hospital, 1035-1039 Via di Grottarossa, 00189Rome, Italy
*
*Corresponding author. [email protected] (I. Pacchiarotti).
Get access

Abstract

A 25-year-old man with DSM-IV-TR Axis I social phobia and Axis II avoidant personality disorder and erectile dysfunction, presenting with depression, anxiety and insomnia, responded partially to extended release oral venlafaxine (75 mg/die for 6 weeks), but developed side effects and worsening symptoms when dose was increased to 150 mg/die; he responded to a combination of 75 mg/die venlafaxine and 4 mg/die reboxetine and improved on most of his symptoms.

Keywords

Social phobiaAvoidant personality disorderSexual dysfunctionVenlafaxineSerotonin-noradrenaline re-uptake inhibitorsReboxetineNoradrenaline re-uptake inhibitors
Type
Case report
Information
European Psychiatry , Volume 19 , Issue 4 , June 2004 , pp. 233 - 234
Copyright
Copyright © European Psychiatric Association 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Altamura, ACPioli, RVitto, MMannu, P.Venlafaxine insocial phobia: a study in selective serotonin reuptake inhibitor non-responders. Int Clin Psychopharmacol 1999;14:239–45.CrossRefGoogle Scholar
Dannon, PNIancu, IGrunhaus, L.The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study. Hum Psychopharmacol Clin Exp 2002;17:329–33.CrossRefGoogle Scholar
Dursun, SMDevarajan, S.Reboxetine plus citalopram for refractory depression not responding to venlafaxine: possible mechanisms. Psy-chopharmacology (Berl) 2001;153:497–8.CrossRefGoogle Scholar
Farina, BDella Marca, GMennuni, GMazza, SDe Risio, SDi Giannantonio, M.The effects of reboxetine on human sleep architecture in depression: preliminary results. J Affect Disord 2002;71: 273–5.CrossRefGoogle ScholarPubMed
Maj, JRogoz, Z.Pharmacological effects of venlafaxine, a new antidepressant, given repeatedly, on the alpha 1-adrenergic, dopamine and serotonin systems. J Neural Transm 1999;106:197–211.CrossRefGoogle ScholarPubMed
Manier, DHShelton, RCSulser, F.Noradrenergic antidepressants: does chronic treatment increase or decrease nuclear CREB-P? J Neural Transm 2002;109:91–9.Google ScholarPubMed
Mathew, SJCoplan, JDGorman, JM.Neurobiological mechanisms of social anxiety disorder. Am J Psychiatry 2001;158:1558–67.CrossRefGoogle ScholarPubMed
Rossby, SPManier, DHLiang, SNalepa, ISulser, F.Pharmacological actions of the antidepressant venlafaxine beyond aminergic receptors. Int J Neuropsychopharmacol 1999;2:1–8.CrossRefGoogle ScholarPubMed
Stahl, SMMendels, JSchwartz, GE.Effects of reboxetine on anxiety, agitation, and insomnia: results of a pooled evaluation of randomized clinical trials. J Clin Psychopharmacol 2002;22:388–92.CrossRefGoogle ScholarPubMed
Versiani, MCassano, GPerugi, GBenedetti, AMastalli, LNardi, Aet al. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry 2002;63:31–7.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.